Gamma's X-SPECT discovers Canada

Gamma Medica Inc. has grabbed its first Canadian installations for its X-SPECT system. The preclinical imaging system has been installed at the London Regional Cancer Program (LRCP), of London, Ontario and McMaster University in Hamilton, Ontario.

London Regional Cancer Program (LRCP), formerly the London Regional Cancer Center, is the cancer services unit of the London Health Sciences Center. LRCP is funded by the Ministry of Health through Cancer Care Ontario and has served the people of Southwestern Ontario since 1952.

"We chose X-SPECT for our pre-clinical work because it will allow us to study candidate molecules for the imaging of tumor biology," said Dr. Albert Driedger, Director of Clinical Research in Nuclear Medicine. "Gamma Medica is the leader in MicroSPECT imaging, and has been able to get us up and running in a very short time."

McMaster University, established in 1887, is one of Canada's top research universities. "This instrument will serve the molecular imaging research needs of a broad range of disciplines including asthma, oncology, molecular medicine, gastrointestinal disease and pediatrics research," said David R. Chettle, PhD, professor, medical physics & applied radiation sciences unit, and director, McMaster Institute of Applied Radiation Sciences.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.